Bristol-Myers Squibb (BMS) has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, to contract manufacturer Catalent Inc.
As part of the acquisition, Catalent will continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site.
Commenting on the acquisition, Alessandro Maselli, Catalent’s President and COO, said: “The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply.”
For Catalent, the Anagni site has a demonstrated track record in technical transfers and successful commercial product launches.
The facility boasts 28,000 sqm (305,000 sqft) of space, and for the CDMO it offers extensive capabilities in aseptic liquid and powder filling for biologics and sterile products across multiple vial sizes, and comprehensive primary and secondary packaging solutions, including serialisation, to support product launches for oral solids, sterile, and biologics products.
Catalent has also announced that it plans to make further investments in the site’s growth.
“Anagni provides our European customers with great biologics and oral dose capabilities that can help us reduce time-to-market, simplify tech transfers, and minimise program risk.”
The divestiture is part of Bristol-Myers Squibb’s strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline.
BMS said the company is focusing resources on its highest priorities of discovering, developing and delivering transformational medicines for patients facing serious diseases.